Acute bacterial skin and skin-structure infections (ABSSSIs) are commonly encountered infections in various healthcare settings \[[@CIT0001]\]. Over the last 2 decades, community-associated methicillin-resistant *Staphylococcus aureus* (MRSA) has emerged as the most common cause of purulent skin infections in the United States with accompanying higher rates of complications (eg, abscess), recurrence, and treatment failures, often leading to hospitalization \[[@CIT0002]\]. The overall burden of managing such common infections has resulted in added healthcare costs \[[@CIT0002]\].

The US Food and Drug Administration (FDA) definition of ABSSSI includes cellulitis/erysipelas, major skin abscesses, and wound infections, with all requiring a minimum lesion surface area of 75 cm^2^ ([Table 1](#T1){ref-type="table"}) \[[@CIT0001], [@CIT0003], [@CIT0004]\]. ABSSSI is a common reason for patients seeking care in various healthcare settings, including emergency departments \[[@CIT0005]\]. Most are treated effectively as outpatients \[[@CIT0001]\]. The decision-making process for admitting patients to the hospital for ABSSSI is complex and often very subjective. In general, patients with all of the following characteristics can be managed as outpatients: no signs of sepsis, low suspicion of deep soft tissue infection including necrotizing fasciitis, and lack of exacerbation of comorbidities. For the majority of patients, empiric treatment is most often directed against gram-positive cocci \[[@CIT0001], [@CIT0006]\].

###### 

US Food and Drug Administration Definition of Acute Bacterial Skin and Structure Infection \[[@CIT0001], [@CIT0004]\]

  Conditions Included in the Definition   Conditions Not Included in the Definition
  --------------------------------------- -------------------------------------------
  Cellulitis/erysipelas                   Impetigo and minor cutaneous abscess
  Wound infections                        Animal or human bites
  Major cutaneous abscess                 Necrotizing fasciitis
                                          Diabetic foot infection
                                          Burns
                                          Chronic wound infection
                                          Myonecrosis
                                          Ecthyma gangrenosum

Reprinted with permission from Russo et al \[[@CIT0001]\].

During hospitalization, healthcare providers may need to reevaluate antimicrobial treatment and the need for surgical intervention \[[@CIT0001]\]. Antimicrobial therapy may need to be adjusted, particularly in the elderly due to comorbidities such as renal insufficiency. Once culture and susceptibility results are available, if indicated, deescalation of antimicrobial therapy is recommended. Of note, the role of MRSA in cellulitis without a wound or purulence is not as clear due to the absence of culturable material.

Here, I review ABSSSI treatment guidelines in the hospital setting and discuss current and future antibiotic options for treatment of this commonly encountered infection. Although many of the studies discussed here have used different terms to describe these infections, such as complicated skin and skin-structure infections or complicated skin and soft-tissue infections, throughout the article I will refer to them as ABSSSI.

TREATMENT GUIDELINES {#s1}
====================

Most recently, the Infectious Diseases Society of America (IDSA) published practice guidelines for the diagnosis and management of ABSSSIs \[[@CIT0006]\]. This publication predates the FDA approval of several newer antibiotics for the treatment of ABSSSIs, including dalbavancin, oritavancin, tedizolid, and delafloxacin. The guidelines divide ABSSSIs into purulent and nonpurulent categories. Cellulitis and erysipelas are considered nonpurulent, while abscesses are categorized as purulent. Vancomycin, linezolid, tigecycline, daptomycin, ceftaroline, and telavancin are all considered appropriate antimicrobial agents for treatment of severe purulent infections, while trimethoprim-sulfamethoxazole and doxycycline are recommended for moderate purulent infections. For methicillin-susceptible *S. aureus* (MSSA), cefazolin and clindamycin are recommended for severe infections and dicloxacillin and cephalexin for moderate infections \[[@CIT0006]\]. Vancomycin plus piperacillin/tazobactam is recommended as a first-line treatment option for severe nonpurulent infections, particularly suspected necrotizing or polymicrobial infections. However, this combination has been associated with an increased risk of acute kidney injury when compared with vancomycin with or without other beta-lactams \[[@CIT0007]\]. Options for treatment of mild to moderate nonpurulent infections include cefazolin, ceftriaxone, clindamycin, and penicillin \[[@CIT0006]\]. Although there is a lack of data to support the optimal duration of antibiotic therapy, the guidelines recommend a treatment duration of 7--10 days \[[@CIT0006]\].

Recent antibiotic development for ABSSSIs has focused largely on the coverage of gram-positive organisms, especially MRSA ([Table 2](#T2){ref-type="table"}) \[[@CIT0008]\]. However, acute skin infections that involve gram-negative pathogens are associated with a potential risk for inadequate antimicrobial therapy. Clinicians need to consider risk factors for infections due to gram-negative pathogens in selected patients \[[@CIT0001]\]. Moreover, although gram-negative pathogens are commonly found in polymicrobial infections, they have also been observed in monomicrobial skin infections \[[@CIT0013], [@CIT0014]\]. Cultures with only gram-negative pathogens have been reported in approximately 13% of patients hospitalized with serious skin infections (not limited to ABSSSI), while mixed cultures have been found in 11%--21% \[[@CIT0015], [@CIT0016]\]. Selection of empiric antibiotic therapy for suspected gram-negative skin infections should be guided by local epidemiologic patterns, as well as infection type and individual patient characteristics \[[@CIT0001], [@CIT0008]\].

###### 

Summary of Recently Approved Antibiotics for the Treatment of Acute Bacterial Skin and Structure Infection \[[@CIT0008]\]

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Product Characteristics   Dalbavancin                                                                                                                           Oritavancin                                                                           Tedizolid                                                                               Delafloxacin
  ------------------------- ------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------
  Indications               ABSSSI caused by susceptible strains of gram-positive microorganisms                                                                  ABSSSI caused by susceptible strains of gram-positive microorganisms                  ABSSSI caused by susceptible strains of gram-positive microorganisms                    ABSSSI caused by susceptible strains of gram-positive and gram-negative microorganisms

  Microbiology              In vitro and clinical activity against the following aerobic and facultative gram-positive bacteria:\                                 In vitro and clinical activity against:\                                              In vitro and clinical activity against gram- positive bacteria including:\              In vitro and clinical activity against the following aerobic gram-positive and gram-negative bacteria:\
                            *• Staphylococcus aureus* (including MRSA)\                                                                                           • *S. aureus*, (including MRSA)\                                                      • *S. aureus* (including MRSA)\                                                         *• S. aureus* (including MRSA)\
                            *• Streptococcus pyogenes*\                                                                                                           • *S. pyogenes*\                                                                      • *S. agalactiae*\                                                                      *• Staphylococcus haemolyticus*\
                            *• Streptococcus agalactiae*\                                                                                                         *• S. agalactiae*\                                                                    *• S. anginosus* group (including *S. anginosus, S. intermedius*, *S. constellatus*)\   *• Staphylococcus lugdunensis*\
                            *• Staphylococcus dysgalactiae*\                                                                                                      *• S. anginosus* group (including *S. anginosus, S. intermedius, S. constellatus*)\   • *S. dysgalactiae*\                                                                    *• S. pyogenes*\
                            *• Staphylococcus anginosus* group (including *Staphylococcus anginosus, Staphylococcus intermedius, Staphylococcus constellatus*)\   • *E. faecalis*                                                                       *• S. pyogenes*\                                                                        *• S. agalactiae*\
                            *• Enterococcus faecalis* (vancomycin- susceptible isolates only)                                                                                                                                                           *• E. faecalis* (vancomycin-susceptible isolates only)                                  *• S. dysgalactiae*\
                                                                                                                                                                                                                                                                                                                                                *• S. anginosus* group *(including S. anginosus, S. intermedius, S. constellatus)*\
                                                                                                                                                                                                                                                                                                                                                *• E. faecalis*\
                                                                                                                                                                                                                                                                                                                                                *• Escherichia coli*\
                                                                                                                                                                                                                                                                                                                                                *• Klebsiella pneumonia*\
                                                                                                                                                                                                                                                                                                                                                *• Enterobacter cloacae*\
                                                                                                                                                                                                                                                                                                                                                *• Pseudomonas aeruginosa*

  Formulations              IV                                                                                                                                    IV                                                                                    IV/oral                                                                                 IV/oral

  Dosing                    Single-dose regimen: 1500 mg IV over 30 min\                                                                                          Single-dose regimen: 1200 mg IV over 3 hours                                          200 mg IV/oral tablet daily for 6 days; IV infusion over 1 hour                         300 mg IV over 60 min every 12 hours for 5--14 days\
                            Two-dose regimen: 1000 mg IV over 30 min followed 1 week later by 500 mg IV over 30 min                                                                                                                                                                                                                             OR\
                                                                                                                                                                                                                                                                                                                                                450 mg oral tablet every 12 hours for 5--14 days
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Abbreviations: ABSSSI, acute bacterial skin and skin-structure infection; IV, intravenous; MRSA, methicillin-resistant *Staphylococcus aureus*.

The emergence of community-associated MRSA strains has greatly influenced the selection of empirical antibiotic therapy for ABSSSIs. To provide adequate empirical coverage for MRSA, an understanding of local microbial epidemiologic patterns and susceptibility patterns is essential \[[@CIT0003]\]. For the treatment of an abscess, the IDSA guidelines recommend, in addition to incision and drainage, administration of an antibiotic active against MRSA when the initial antibiotic treatment has failed or when the patient has immunosuppression, systemic inflammatory response syndrome (SIRS), or hypotension \[[@CIT0006]\]. For cellulitis and erysipelas, including an antibiotic with activity against MRSA and group A streptococcus is recommended when the infection is associated with penetrating trauma or when there is evidence of MRSA infection, MRSA colonization, injecting drug use, or SIRS \[[@CIT0006]\]. Further, including an antimicrobial agent active against MRSA in the treatment of surgical wound infections is recommended in patients with risk factors for infection by this microorganism (nasal colonization or prior infection, hospitalization, or recent antibiotic administration) \[[@CIT0006]\]. Anti-MRSA agents for ABSSSIs include vancomycin, which is considered the first-line parenteral treatment of serious MRSA infections in hospitalized patients, as well as linezolid, daptomycin, and tigecycline ([Table 3](#T3){ref-type="table"}) \[[@CIT0006]\]. Other agents with reliable MRSA activity that have been approved for ABSSSIs include ceftaroline, tedizolid, dalbavancin, oritavancin, and telavancin. Additional factors for administering these medications include tolerability, formulation, cost, and dosing limitations associated with these agents, such as vancomycin-related nephrotoxicity and linezolid-associated myelosuppression.

###### 

2014 Infectious Diseases Society of America Recommendations for Antibiotic Treatment of Acute Bacterial Skin and Structure Infection Caused by Methicillin-resistant *Staphylococcus aureus* \[[@CIT0006]\]

  ------------------------------------------------------------------------------------
  Antibiotic                      Route     Recommended Dosing in Adults
  ------------------------------- --------- ------------------------------------------
  Vancomycin                      IV        15 mg/kg every 12 hours

  Linezolid                       IV/oral   IV: 600 mg every 12 hours\
                                            Oral: 600 mg twice a day

  Clindamycin                     IV/oral   IV: 600 mg every 8 hours\
                                            Oral: 300--450 mg 4 times a day

  Daptomycin                      IV        4 mg/kg daily

  Ceftaroline                     IV        600 mg every 12 hours

  Doxycycline, minocycline        Oral      100 mg twice a day

  Trimethoprim-sulfamethoxazole   Oral      1--2 double strength tablets twice a day
  ------------------------------------------------------------------------------------

Abbreviations: IV, intravenous.

ANTIBIOTIC TREATMENT OPTIONS FOR ABSSSI {#s2}
=======================================

Beta-lactams {#s3}
------------

Among the beta-lactams, ceftaroline fosamil is an option for the initial empirical treatment of patients hospitalized with ABSSSIs, including those with suspected MRSA infection. Ceftaroline, administered twice daily, is an advanced-generation, intravenous (IV), bactericidal cephalosporin with broad-spectrum activity against gram-positive bacteria, including MRSA and some gram-negative bacteria, with the exception of *Pseudomonas aeruginosa* \[[@CIT0017]\]. In 2 phase 3 studies \[[@CIT0018], [@CIT0019]\], ceftaroline showed noninferiority to vancomycin plus aztreonam in hospitalized patients with ABSSSI. Diarrhea was the most commonly reported adverse event (AE), and there was a low incidence of *Clostridium difficile*-associated diarrhea \[[@CIT0018], [@CIT0019]\]. Ceftaroline has also demonstrated a low potential for the selection of in vitro resistance for drug-resistant gram-positive organisms, including MRSA \[[@CIT0017]\]. There is no oral formulation of ceftaroline.

Cyclic Lipopeptides {#s4}
-------------------

Daptomycin is a cyclic lipopeptide that is dosed once daily and exhibits rapid, concentration-dependent bactericidal activity against a broad range of gram-positive pathogens, including MRSA and vancomycin-resistant pathogens \[[@CIT0020]\]. In 2 trials, the clinical success rate for daptomycin in patients with ABSSSIs was 83.4% with a shorter duration of treatment than comparator antibiotics \[[@CIT0021]\]. A randomized, controlled trial demonstrated that in patients admitted to an observation unit with ABSSSI, IV daptomycin was noninferior to vancomycin for the primary endpoint of objective discharge criteria with no change in antibiotic therapy or return to the emergency department for the same cellulitis within 30 days of discharge \[[@CIT0022]\]. The most notable side effect of daptomycin is myotoxicity, which is reversible upon discontinuation of therapy \[[@CIT0020]\].

Fluoroquinolones {#s5}
----------------

Fluoroquinolones such as ciprofloxacin, levofloxacin, and moxifloxacin are not commonly utilized as treatment agents for ABSSSIs caused by MRSA and are not endorsed in the IDSA guidelines as such. This is primarily due to decreased susceptibility of MRSA to fluoroquinolones, which highlights the need for additional treatment options for skin infections that are caused by fluoroquinolone-resistant organisms \[[@CIT0023]\]. Delafloxacin is a novel non-zwitterionic fluoroquinolone approved by the FDA in 2017 for ABSSSIs \[[@CIT0008]\]. Delafloxacin has broad-spectrum activity that allows for potential use in infections caused by gram-positive pathogens, including MRSA and many gram-negative pathogens, without the need for combination therapy \[[@CIT0008], [@CIT0023]\]. Delafloxacin can be administered IV or orally \[[@CIT0023]\]. The chemical profile of delafloxacin is unique among quinolones, which makes it particularly active in acidic environments \[[@CIT0024], [@CIT0025]\]. Delafloxacin demonstrates greater in vitro and in vivo activity against the majority of gram-positive pathogens compared with levofloxacin, including MRSA isolates and isolates not susceptible to levofloxacin \[[@CIT0023], [@CIT0026]\].

Two phase 3, randomized, double-blind, active-controlled studies demonstrated that delafloxacin was noninferior to the combination of vancomycin plus aztreonam for the treatment of ABSSSIs \[[@CIT0008], [@CIT0027]\]. These trials compared delafloxacin with vancomycin plus aztreonam for a period of 5--14 days. The primary efficacy endpoint of objective response rate 48--72 hours after treatment initiation was 78.2% in the delafloxacin arm and 80.9% in the vancomycin/aztreonam arm (mean treatment difference, --2.6%; 95% confidence interval \[CI\], --8.78% to 3.57%) in the first trial \[[@CIT0008]\] and 83.7% and 80.6% (mean treatment difference, 3.1%; 95% CI, --2.0% to 8.3%) in the second trial \[[@CIT0027]\]. Cure rates in those with MRSA infection were similar between the delafloxacin group (100%) and the vancomycin/aztreonam group (98.5%). The rate of treatment-emergent AEs was similar in both arms. AEs that resulted in treatment discontinuation were higher in the vancomycin plus aztreonam group compared with the delafloxacin group (4.3% vs 0.9%) \[[@CIT0008]\].

Several studies have demonstrated minimal potential for drug--drug interactions with delafloxacin, as well as no evidence of QT interval prolongation or phototoxicity \[[@CIT0028]\]. There is no apparent effect of food or age on delafloxacin pharmacokinetics, and weight-based dosing and drug monitoring are not required.

Glycopeptides {#s6}
-------------

The IDSA guidelines recommend vancomycin as a first-line agent for ABSSSIs caused by MRSA \[[@CIT0006]\]. Nephrotoxicity is the most serious AE associated with vancomycin, and risk factors can include the higher doses and prolonged treatment, high serum trough concentrations, and concurrent administration of nephrotoxic agents \[[@CIT0032]\]. The combination of vancomycin with piperacillin-tazobactam, which is frequently used to cover relevant gram-negative pathogens, has been shown to be associated with acute kidney injury \[[@CIT0007]\]. Vancomycin-associated nephrotoxicity has been linked to longer hospital stays, increased medical costs, need for additional antibiotics, and, in rare cases, dialysis \[[@CIT0032]\]. Since elevated trough concentrations of vancomycin are associated with a higher incidence of nephrotoxicity, careful monitoring of these concentrations is required. Consensus guidelines for vancomycin therapeutic monitoring recommend targeting trough concentrations of 15--20 mg/L to limit nephrotoxicity. In addition, concentrations ≥10 mg/L are recommended to prevent development of bacterial strains resistant to vancomycin \[[@CIT0033], [@CIT0034]\]. Vancomycin-resistant *Enterococcus* (VRE) species have been reported in monomicrobial ABSSSIs \[[@CIT0035]\], and vancomycin-intermediate and vancomycin-resistant *S. aureus* also present treatment challenges.

Telavancin is another member of the lipoglycopeptide class and a semisynthetic derivative of vancomycin \[[@CIT0036]\]. It exhibits activity against a broad range of gram-positive organisms, including *S. aureus*, coagulase-negative staphylococci, and *Streptococcus* species. It has activity against MRSA, vancomycin-intermediate *S. aureus*, vancomycin-susceptible and VRE species, and various other gram-positive anaerobic organisms \[[@CIT0036]\]. In a metaanalysis of randomized trials, telavancin showed higher eradication rates (odds ratio \[OR\] = 1.71 \[1.08--2.70\]) and a trend toward better clinical response compared with vancomycin (OR = 1.55 \[0.93--2.58\]) \[[@CIT0036]\]. This analysis also showed that telavancin was associated with higher rates of serious AEs, the most common of which were renal in nature.

Glycylcyclines {#s7}
--------------

Tigecycline is an IV broad-spectrum glycylcycline that exhibits in vitro activity against gram-positive, gram-negative, anaerobic, and atypical organisms and some multidrug-resistant pathogens \[[@CIT0037]\]. It is unaffected by standard tetracycline resistance mechanisms and has not shown any cross-resistance with common resistance mechanisms seen with other antibiotic classes, although resistance through specific efflux pump mechanisms has been reported \[[@CIT0037]\]. Two randomized, double-blind trials found tigecycline to be noninferior to the combination of vancomycin and aztreonam in adults for the treatment of ABSSSIs \[[@CIT0038], [@CIT0039]\], and a more recent randomized study showed it to be noninferior to ampicillin/sulbactam or amoxicillin-clavulanate with or without vancomycin in the treatment of ABSSSIs \[[@CIT0037]\]. The most commonly observed AEs are nausea and vomiting. Cases of acute pancreatitis following tigecycline administration have been observed \[[@CIT0040]\].

Lipoglycopeptides {#s8}
-----------------

The lipoglycopeptide class is comprised of 2 IV options: dalbavancin and oritavancin. Dalbavancin has activity against most gram-positive pathogens and possesses a long plasma half-life (6--10 days) \[[@CIT0041]\]. A 2-dose regimen of IV dalbavancin, given on day 1 (1 gram) and day 8 (0.5 gram), has been shown to be noninferior to twice-daily vancomycin followed by oral linezolid for the treatment of ABSSSI, with less frequent AEs \[[@CIT0042]\]. The most common treatment-related AEs in either group were nausea, diarrhea, and pruritis \[[@CIT0042]\]. Additionally, a single-dose infusion of dalbavancin has shown to have noninferior efficacy to the 2-dose dalbavancin regimen with respect to early clinical response, with a similar safety profile \[[@CIT0043]\].

Oritavancin has activity against gram-positive organisms, and its long elimination half-life allows for single-dose treatment \[[@CIT0044]\]. The safety of oritavancin was evaluated in 2 phase 3 studies enrolling 976 oritavancin patients and 983 vancomycin patients \[[@CIT0044]\]. From the safety database, the incidences of AEs, serious AEs, and discontinuations due to AEs were similar for oritavancin and vancomycin. The most frequently reported AEs were nausea, headache, and vomiting \[[@CIT0044]\]. Single-dose oritavancin has shown similar efficacy to that of twice-daily vancomycin at both early clinical and end-of-therapy time points \[[@CIT0045]\]. Oritavancin also has activity against *vanA*-mediated VRE species \[[@CIT0046]\].

Oxazolidinones {#s9}
--------------

Linezolid is available in IV and oral formulations \[[@CIT0047]\]. Linezolid provides an option for early switch to oral therapy, and dose reduction is not necessary in patients with renal insufficiency \[[@CIT0040]\]. Linezolid has shown to be active against many resistant gram-positive organisms including MRSA, VRE, and macrolide-resistant streptococci. In a study of patients with ABSSSIs due to MRSA, compared with vancomycin, linezolid-treated patients had significantly higher clinical and microbiological success rates at the end of treatment \[[@CIT0048]\]. Linezolid-associated thrombocytopenia and anemia are typically mild, reversible, and duration dependent \[[@CIT0049]\]. There is an interaction between linezolid and selective serotonin reuptake inhibitors.

Tedizolid, a bacterial protein synthesis inhibitor, can be administered once daily, either orally or IV at equivalent doses \[[@CIT0050]\]. In 2 randomized trials, treatment with tedizolid for 6 days was shown to be noninferior to linezolid for 10 days \[[@CIT0051], [@CIT0052]\]. In addition, differences in the incidence of gastrointestinal AEs have been observed between tedizolid and linezolid \[[@CIT0050]\], possibly due to the effects of these agents on intestinal flora \[[@CIT0050]\]. The effect of tedizolid on normal intestinal flora has been shown to be limited and reversible \[[@CIT0053]\], and another study showed that linezolid led to marked changes in gut flora composition \[[@CIT0054]\]. Further, the less frequent dosing with tedizolid (once daily vs twice daily with linezolid) may also somewhat reduce the overall risk of developing gastrointestinal AEs \[[@CIT0050]\].

Trimethoprim-sulfamethoxazole and Clindamycin {#s10}
---------------------------------------------

Several recent trials have evaluated the efficacy and safety of trimethoprim-sulfamethoxazole and clindamycin for the treatment of uncomplicated ABSSSIs \[[@CIT0055]\]. In a study of uncomplicated cutaneous abscesses treated with drainage, adjunctive treatment with trimethoprim-sulfamethoxazole for 7 days resulted in higher cure rates compared with placebo. In another randomized study of uncomplicated wound infections, trimethoprim-sulfamethoxazole and clindamycin were similarly effective with comparable cure rates and AEs \[[@CIT0056]\]. A randomized clinical trial involving adults and children found no differences between clindamycin and trimethoprim-sulfamethoxazole in efficacy or safety for the treatment of uncomplicated skin infections. However, the development of new infections by 1 month of follow-up was lower in the clindamycin-treated group \[[@CIT0057]\]. Neither of these 2 antibiotics has been evaluated in a head-to-head comparison with the newer MRSA-active antibiotics.

INVESTIGATIONAL AND RECENTLY APPROVED ANTIBIOTICS FOR ABSSSI {#s11}
============================================================

Aminomethylcyclines: Omadacycline {#s12}
---------------------------------

Omadacycline is a first-in-class broad-spectrum aminomethylcycline \[[@CIT0058]\]. Similar to tetracyclines, omadacycline binds to the 30S ribosomal subunit of target gram-positive and gram-negative bacteria, resulting in inhibition of protein synthesis \[[@CIT0058]\]. Omadacycline has high potency against MRSA and MSSA and maintains activity in the presence of ribosomal protection and efflux tetracycline resistance genes. It has proven activity against tetracycline-resistant pathogens and is not affected by mechanisms of resistance to other classes of antibacterial agents \[[@CIT0058]\]. The pharmacologic properties of omadacycline allow for IV or oral administration with once-daily dosing. Omadacycline was shown to be well tolerated and effective for the treatment of complicated skin infections in a phase 2, randomized, investigator-blind, multicenter trial \[[@CIT0059]\]. There were fewer treatment-related AEs in omadacycline-treated patients (21%) compared with the linezolid group (30.6%), the most common of which were GI related (18.9% omadacycline, 18.5% linezolid).

Pleuromutilins: Lefamulin {#s13}
-------------------------

Lefamulin is currently in late stage development as an IV and oral treatment for ABSSSIs \[[@CIT0060]\]. Lefamulin inhibits protein synthesis by binding to the 50S ribosomal subunit \[[@CIT0061]\]. It exhibits activity against frequently identified gram-positive skin pathogens, including MRSA, MSSA, *Streptococcus pyogenes*, *Streptococcus agalactiae*, and vancomycin-resistant *Enterococcus faecium* \[[@CIT0062]\].

Pleuromutilins are not affected by resistance mechanisms involving major antibiotic classes, including fluoroquinolones and tetracyclines \[[@CIT0060]\]. A phase 2 proof-of-concept study evaluated the use of lefamulin vs vancomycin in the treatment of patients with ABSSSIs caused by a gram-positive pathogen. In that trial, 207 patients were randomized to IV lefamulin 100 mg, lefamulin 150 mg, or vancomycin 1 g every 12 hours. Clinical success rates at test-of-cure in the clinically evaluable population were comparable across all 3 groups: 90% lefamulin 100 mg group; 88.9% lefamulin 150 mg group, and 92.2% vancomycin group. In addition, clinical response rates at day 3 were similar across the 3 treatment groups. The incidence of drug-related AEs was lower for lefamulin (34.3% and 39.4% in the 100 mg and 150 mg groups, respectively) compared with vancomycin (53.0%) \[[@CIT0062]\].

CONCLUSIONS {#s14}
===========

ABSSSIs pose a significant burden to the healthcare system. The challenge of treating these infections has been lessened by recent development of new antibiotic treatment options that target gram-positive organisms including MRSA strains. However, new antibiotics that can cover both gram-positive pathogens (including MRSA) and gram-negative pathogens can fulfill an important need in the treatment of selected hospitalized patients with acute skin infections. Examples of such infections include abscesses with mixed bacterial growth, surgical-site infections, particularly those related to abdominal surgery, and selected acute skin infections in patients with diabetes. Furthermore, antibiotics that can offer hospital clinicians other attributes, such as the flexibility to transition from IV to oral formulation, infrequent dosing, pharmacokinetics that are unaffected by various patient characteristics, a low risk of drug--drug interactions, and no requirement for therapeutic monitoring, will be particularly useful when treating ABSSSIs.
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